AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02730377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT-2 inhibitors
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study NCT02730377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study NCT02730377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazolidinediones
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study NCT02402023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: CM is standard care plus monetary payment delivered contingent on abstinence.
Study NCT02402023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care (SC)
Description: Standard of care consists of smoking cessation counseling sessions and nicotine patches.
Study NCT02402023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SC)
Description: Standard of care consists of smoking cessation counseling sessions and nicotine patches.
Study NCT01328899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Coil (LVRC) (PneumRx's)
Description: Lung Volume Reduction Coil
Study NCT01846481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-8000 100 mg
Description: RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
Study NCT01846481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
Study NCT01846481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: 50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
Study NCT01846481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-8000 200 mg
Description: RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
Study NCT02928783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Study NCT03747068 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF Drug
Study NCT02718690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT02718690 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT03463707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP101
Description: Investigational product BP101, nasal spray
Study NCT03463707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Investigational product BP101, nasal spray
Study NCT02183259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR 1150 CL, Capsule, oral
Study NCT02183259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR 1150 CL, solution, intravenous
Study NCT01125670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT04775901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CT-guided lung biopsy
Description: Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
Study NCT04775901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Template-guided lung biopsy
Description: A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
Study NCT01337713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish Massage
Description: Swedish massage, 45 minutes, 2 x per week for 6 weeks
Study NCT01337713 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch
Description: Light touch, 45 minutes, 2 x week for 6 weeks
Study NCT03555864 — intervention group
Intervention type: DEVICE
Intervention: infrared transluminescent device
Description: use of infra red for venous access for second intravenous access
Study NCT03076788 — intervention group
Intervention type: OTHER
Intervention: electrocardiogram and echocardiography
Description: We retrieved all electrocardiograms and echocardiography made during the clinical examination of each athlete and each sedentary control.~* Standard 12 lead ECG~* Trans-thoracic echocardiography examination of cardiac function, morphology and intracardiac flow.
Study NCT02888392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiwifruit
Description: 2 green kiwifruit cultivar 'Hayward'
Study NCT02888392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
Study NCT03425266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive decision support tool
Description: PainApp 1) assesses patient treatment goals (a structured values clarification exercise) and preferences, including decision making and communication preferences; 2) presents structured educational modules tailored to the user's stated goals and preferences; 3) presents educational information addressing identified gaps in care and communication; 4) assesses pain, pain interference, function, and other clinical factors; 5) generates succinct individualized summaries of patient treatment preferences and medical history, tailored to different clinical settings; 6) generates a personalized report for the patient, based on their goals and interests; 7) transmits the clinical summary to the patient and their provider(s), with patient permission.
Study NCT01521156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).
Description: 1 = Intervention 1 (1 test product/day)
Study NCT01521156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).
Description: 2 = Intervention 2 (1 test product/day)
Study NCT02071706 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI system
Description: Enrolled subject undergoes PET/MR scan
Study NCT01070667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: 400mg orally once per day for 3 months
Study NCT01070667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
Study NCT03815591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smokeSCREEN web-based game
Description: smokeSCREEN tobacco use reduction/prevention web-based game. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
Study NCT04173728 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard mixed macronutrients tolerance test
Description: Consumption a standard mixture containing 75g glucose, 60g fat and 20 protein.
Study NCT03020875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofirmev
Description: Intravenously administered acetaminophen.
Study NCT03020875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Per Os Acetaminophen
Description: Orally administered acetaminophen.
Study NCT00655148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV vero vaccine
Description: DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
Study NCT00655148 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV mkc vaccine
Description: DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
Study NCT05269420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAS-J
Description: Single Anastomosis Sleeve Jejunal Bypass
Study NCT04446650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Oral
Study NCT03028857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline
Description: Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
Study NCT03028857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
Study NCT04507802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation via helmet
Description: Patients requiring long hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet
Study NCT02344394 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermocool Catheter
Description: For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
Study NCT02344394 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nContact
Description: For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
Study NCT06624501 — intervention group
Intervention type: OTHER
Intervention: Observational cohort study
Study NCT03651063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: social robot
Description: Reach To Grasp games with a social robot
Study NCT05803447 — intervention group
Intervention type: OTHER
Intervention: Interview questionnaire
Description: An Interview questionnaire concerning an assessment of the intensity suicidal behavior, M.I.N.I. 7.0.2 was used.~M.I.N.I. interview was conducted with each patient to verify the intensification of suicidal behaviour.
Study NCT05803447 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the:~* blood serum: vitamin D3, B12, folic acid, sodium, potassium, calcium, magnesium, chlorine, total cholesterol, LDL and HDL fractions, TG~* plasma: metabolites of the oxidative stress
Study NCT05803447 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cognitive function
Description: The participants completing cognitive function were assessed using computer CogState Test. The following cognitive functions were assessed: psychomotor drive (DET), metastability of attention (IDN), verbal memory, retrieval of learned material (ISLR) and verbal learning and memory (ISL), visual learning and memory (OCL), processing speed (GMCT), visual memory including deferred retrieval (GMR), executive functions (SETS and GML), working memory (ONB, TWOB).
Study NCT05905666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education and counseling
Description: In the control stage, participants only received standard nursing care. In the experimental stage, intervention measures (health education and counseling) were implemented. The baseline data were the pretest data collected in the control stage. Four weeks later, a posttest was performed, namely the pretest of the experimental stage. Subsequently, 4 weeks of health education and counseling were introduced to smokers according to different stages. After 4 weeks of intervention, participants were asked to fill out the posttest questionnaire again to measure the stages of change for smoking cessation, smoking decisional balance, and self-efficacy of smoking cessation.
Study NCT00169715 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Caliceal Diverticuli
Description: Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
Study NCT02228304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-503-3 ECT implantation
Description: NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
Study NCT02228304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea® injected intravitreally administered every 8 weeks
Description: The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
Study NCT04207931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical steroid class I-II
Description: applied once daily - 18 month duration of the study
Study NCT04207931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intralesional Steroid Injection, 7.5mg/cc. max dose of 3 cc. Scalp injections will be administered every 6-8 weeks, for a total of 8 injections.
Study NCT04207931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycyline
Description: oral antibiotic twice daily for 6 months
Study NCT04207931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: 5% solution or foam started after month 8
Study NCT03886961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reflux Band
Description: The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.
Study NCT00774254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A
Description: Intervention
Study NCT00774254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B
Description: Intervention
Study NCT03912714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Surgery will be performed under general anaesthesia. The laparoscopic appendectomy can be performed with the use of 3 trocars; one subumbilical, one suprapubic and one in the lower right quadrant of the abdomen. The appendix is removed using a laparoscopic endostapler enabling a safe and complete appendectomy with the cross stapling line at coecal base. Laparoscopic appendectomy will be performed by a gastrointestinal surgeon with sufficient experience in laparoscopic appendectomies (>20).
Study NCT03912714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic appendix biopsies
Description: Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
Study NCT03912714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic appendix biopsies
Description: Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
Study NCT04202913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Child will receive 1:1 coaching with health coach.
Study NCT01351480 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: abatacept
Description: Abatacept administered SC weekly at 125 mg dose
Study NCT04402996 — intervention group
Intervention type: OTHER
Intervention: Saliva
Description: individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.
Study NCT04402996 — intervention group
Intervention type: OTHER
Intervention: gingival crevicular fluid
Description: GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.
Study NCT04294706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hemp arm
Description: Hemp oil
Study NCT04294706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hemp arm
Description: Hemp oil
Study NCT05526807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Oral
Study NCT03523143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early screening and intervention
Description: The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
Study NCT03523143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard screening and intervention
Description: The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
Study NCT00893997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR-1 vaccine
Description: 0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
Study NCT03455010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased load
Description: Participants walk with 120% body weight achieved with a weight vest
Study NCT03455010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced load
Description: Participants walk with 80% body weight achieved by a dynamic unloading system
Study NCT00922467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9/00
Description: Same volume as in the esmolol group
Study NCT00922467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: 1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
Study NCT02581475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extending withdrawal time in the proximal colon
Study NCT02581475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmental examination twice of the proximal colon
Study NCT04332341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Description: Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
Study NCT03737708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Administered orally
Study NCT03737708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Administered orally
Study NCT03737708 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Administered as subcutaneous injection
Study NCT03737708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Administered as subcutaneous injection